Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 150

1.

Apolipoprotein profiles in subjects with and without peripheral artery disease.

Gardner AW, Alaupovic P, Parker DE, Montgomery PS, Roof A, Casanegra AI.

Vasc Med. 2013 Jun;18(3):129-35. doi: 10.1177/1358863X13489768.

2.
3.
5.

Apolipoprotein B100 is a better treatment target than calculated LDL and non-HDL cholesterol in statin-treated patients.

Soran H, France MW, Kwok S, Dissanayake S, Charlton-Menys V, Younis NN, Durrington PN.

Ann Clin Biochem. 2011 Nov;48(Pt 6):566-71. doi: 10.1258/acb.2011.010277. Epub 2011 Oct 17.

PMID:
22006975
6.

Association of LDL cholesterol, non-HDL cholesterol, and apolipoprotein B levels with risk of cardiovascular events among patients treated with statins: a meta-analysis.

Boekholdt SM, Arsenault BJ, Mora S, Pedersen TR, LaRosa JC, Nestel PJ, Simes RJ, Durrington P, Hitman GA, Welch KM, DeMicco DA, Zwinderman AH, Clearfield MB, Downs JR, Tonkin AM, Colhoun HM, Gotto AM Jr, Ridker PM, Kastelein JJ.

JAMA. 2012 Mar 28;307(12):1302-9. doi: 10.1001/jama.2012.366. Erratum in: JAMA. 2012 May 9;307(18):1915. JAMA. 2012 Apr 25;307(16):1694.

PMID:
22453571
7.

ApoB/A1 and LDL-C/HDL-C and the prediction of cardiovascular risk in statin-treated patients.

Liem AH, van de Woestijne AP, Roeters van Lennep HW, Zwinderman AH, van der Steeg WA, Jukema JW.

Curr Med Res Opin. 2008 Feb;24(2):359-64.

PMID:
18081989
8.

Influence of peripheral artery disease and statin therapy on apolipoprotein profiles.

Gardner AW, Alaupovic P, Parker DE, Montgomery PS, Esponda OL, Casanegra AI.

Int J Vasc Med. 2013;2013:548764. doi: 10.1155/2013/548764. Epub 2013 Sep 11.

9.

HMG-CoA reductase inhibitor (Statin) therapy and coronary atherosclerosis in Japanese subjects: role of high-density lipoprotein cholesterol.

Tani S, Nagao K, Hirayama A.

Am J Cardiovasc Drugs. 2011 Dec 1;11(6):411-7. doi: 10.2165/11594620-000000000-00000.

PMID:
22149320
10.

Pitavastatin: novel effects on lipid parameters.

Chapman MJ.

Atheroscler Suppl. 2011 Nov;12(3):277-84. doi: 10.1016/S1567-5688(11)70887-X. Review.

PMID:
22152282
11.

The effects on lipid and apolipoprotein serum levels of long-term carbamazepine, valproic acid and phenobarbital therapy in children with epilepsy.

Eirís J, Novo-Rodríguez MI, Del Río M, Meseguer P, Del Río MC, Castro-Gago M.

Epilepsy Res. 2000 Aug;41(1):1-7.

PMID:
10924863
12.
13.

Lipids, apolipoproteins, and their ratios in relation to cardiovascular events with statin treatment.

Kastelein JJ, van der Steeg WA, Holme I, Gaffney M, Cater NB, Barter P, Deedwania P, Olsson AG, Boekholdt SM, Demicco DA, Szarek M, LaRosa JC, Pedersen TR, Grundy SM; TNT Study Group; IDEAL Study Group.

Circulation. 2008 Jun 10;117(23):3002-9. doi: 10.1161/CIRCULATIONAHA.107.713438. Epub 2008 Jun 2.

14.

Apolipoprotein concentrations during treatment and recurrent coronary artery disease events.

van Lennep JE, Westerveld HT, van Lennep HW, Zwinderman AH, Erkelens DW, van der Wall EE.

Arterioscler Thromb Vasc Biol. 2000 Nov;20(11):2408-13.

15.

Low-Density Lipoprotein Cholesterol, Non-High-Density Lipoprotein Cholesterol, Triglycerides, and Apolipoprotein B and Cardiovascular Risk in Patients With Manifest Arterial Disease.

van den Berg MJ, van der Graaf Y, de Borst GJ, Kappelle LJ, Nathoe HM, Visseren FLJ; SMART Study Group.

Am J Cardiol. 2016 Sep 15;118(6):804-810. doi: 10.1016/j.amjcard.2016.06.048. Epub 2016 Jun 28.

16.

Levels and changes of HDL cholesterol and apolipoprotein A-I in relation to risk of cardiovascular events among statin-treated patients: a meta-analysis.

Boekholdt SM, Arsenault BJ, Hovingh GK, Mora S, Pedersen TR, Larosa JC, Welch KM, Amarenco P, Demicco DA, Tonkin AM, Sullivan DR, Kirby A, Colhoun HM, Hitman GA, Betteridge DJ, Durrington PN, Clearfield MB, Downs JR, Gotto AM Jr, Ridker PM, Kastelein JJ.

Circulation. 2013 Oct 1;128(14):1504-12. doi: 10.1161/CIRCULATIONAHA.113.002670. Epub 2013 Aug 21.

17.

Effects of simvastatin on plasma lipids and apolipoproteins in familial hypercholesterolemic swine.

Hasler-Rapacz J, Kempen HJ, Princen HM, Kudchodkar BJ, Lacko A, Rapacz J.

Arterioscler Thromb Vasc Biol. 1996 Jan;16(1):137-43.

18.

Simvastatin, transdermal patch, and oral estrogen-progestogen preparation in early-postmenopausal hypercholesterolemic women: a randomized, placebo-controlled clinical trial.

Vigna GB, Donegà P, Zanca R, Barban A, Passaro A, Pansini F, Bonaccorsi G, Mollica G, Fellin R.

Metabolism. 2002 Nov;51(11):1463-70.

PMID:
12404199
19.

Effects of ezetimibe, simvastatin and ezetimibe/simvastatin on correlations between apolipoprotein B, LDL cholesterol and non-HDL cholesterol in patients with primary hypercholesterolemia.

Farnier M, Guyton JR, Jensen E, Polis AB, Johnson-Levonas AO, Brudi P.

Atherosclerosis. 2013 Aug;229(2):415-22. doi: 10.1016/j.atherosclerosis.2013.05.010. Epub 2013 Jun 5.

PMID:
23880197
20.

Lipoprotein(a) particle concentration and lipoprotein(a) cholesterol assays yield discordant classification of patients into four physiologically discrete groups.

Konerman M, Kulkarni K, Toth PP, Jones SR.

J Clin Lipidol. 2012 Jul-Aug;6(4):368-73. doi: 10.1016/j.jacl.2012.01.004. Epub 2012 Jan 21.

PMID:
22836074

Supplemental Content

Support Center